Cambrex High Point, Inc. Applies to Import Controlled Substance for Research
Estimated reading time: 1–7 minutes
Cambrex High Point, Inc. has filed an application to be registered as an importer of a controlled substance. The application was officially submitted on July 16, 2025.
The company’s address is 4180 Mendenhall Oaks Parkway, High Point, North Carolina, 27265-8017.
Cambrex High Point, Inc. wants to import poppy straw concentrate, which is listed as a Schedule II drug. The specific drug code for poppy straw concentrate is 9670.
This substance will only be used for research and development purposes. The registration does not allow any other activity for this drug code.
No approval is given to import Food and Drug Administration (FDA)-approved or non-approved finished dosage forms this registration. These cannot be imported for commercial sale.
The United States Drug Enforcement Administration (DEA) is handling this application. Bulk manufacturers and other applicants can send electronic comments or objections on this registration. They may also ask for a hearing.
The last day to submit comments or hearing requests is September 22, 2025.
All comments must be sent in electronically through the Federal eRulemaking Portal at https://www.regulations.gov. A Comment Tracking Number will be given after submitting a comment.
Requests for a hearing must also go to the Drug Enforcement Administration at 8701 Morrissette Drive, Springfield, Virginia 22152. These requests should go to the Hearing Clerk/OALJ, the DEA Federal Register Representative/DPW, and the Administrator at the same address.
Approval of permit applications will happen only if the business activity matches what is allowed under United States law 21 U.S.C. 952(a)(2).
The notice was issued by Justin Wood, Acting Deputy Assistant Administrator at the DEA.
This information was published in the Federal Register, Volume 90, Number 160, on August 21, 2025.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
